EPIC study: Pre-existing cardiometabolic diseases impact cancer stage
EPIC study: Pre-existing cardiometabolic diseases impact cancer stage
Individualised breast cancer risk assessment model for BreastScreen Norway
Choosing wisely: Breast cancer
Complex technologies for advanced diagnosis and precision medicine in oncology
Intraoperative Radiotherapy
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer
Cancer survivors' stories: An African perspective
ESMO 2022: Breast and ovarian trial analysis
ESMO 2022: Highlights, commentary and analysis
ESMO 2022: Breast cancer highlights
Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data
Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial